Vagus nerve

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

Retrieved on: 
Thursday, March 21, 2024

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has been accepted into the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).
  • The FDA’s Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite development and patient access to safe and effective high-quality medical devices upon FDA approval.
  • In October 2023, the FDA expanded the program to include neurological and physical medicine devices.
  • SetPoint's integrated neurostimulation device uses precise vagus nerve stimulation to activate innate anti-inflammatory and immune-restorative pathways to treat autoimmune conditions.

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on: 
Wednesday, March 20, 2024

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points: 
  • Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
  • VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
  • VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
  • For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

Retrieved on: 
Wednesday, March 13, 2024

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).
  • Breakthrough Device Designation will enable interactive communication and priority regulatory review with the FDA, and support reimbursement and patient access upon FDA approval of SetPoint’s technology.
  • This Breakthrough Device Designation is based on evidence demonstrating that SetPoint's treatment has the potential to reduce demyelination and promote remyelination.
  • In 2020, the FDA also granted Breakthrough Device Designation to SetPoint's device for the treatment of rheumatoid arthritis (RA).

Groundbreaking Non-Invasive Migraine and Cluster Headache Treatment Now Offered Nationally by Dr. David Mahjoubi.

Retrieved on: 
Tuesday, March 26, 2024

LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches- gammaCore Sapphire™. This revolutionary therapy marks a significant milestone in the pursuit of effective and holistic solutions for chronic headache sufferers.

Key Points: 
  • LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches - gammaCore Sapphire™.
  • "We are thrilled to offer gammaCore Sapphire™ as part of our comprehensive approach to wellness, says Dr. David Mahjoubi, a board-certified Anesthesiologist.
  • Migraine and cluster headaches affect millions of individuals worldwide, often leading to debilitating pain and disrupting daily activities.
  • The clinic also offers a range of other services, including IV and Ketamine therapy , and now gammaCore Sapphire™ for migraine and cluster headache relief.

Finding joy in the little things really can benefit your wellbeing – a scientist explains

Retrieved on: 
Wednesday, February 14, 2024

This piece of folk advice has been around for aeons, and is one that many of us try to live by.

Key Points: 
  • This piece of folk advice has been around for aeons, and is one that many of us try to live by.
  • But is there actually any real benefit to this practice?
  • According to research, yes, there is indeed some benefit to savouring fleeting moments of joy – also known as “micro-joys”.
  • Some studies suggest a magic number: five positive emotions to one negative emotion for optimal wellbeing.


Better self-regulation has a ripple effect on various aspects of our lives – such as preventing addiction or self-defeating behaviours (including procrastination, blame and perfectionism). Making time to do even just small, personal tasks such as making lists, tracking daily budgets and even working on your posture each day can help strengthen your self-regulation and ward off against failures.

Finding micro-joy

  • First, research suggests that some people’s genetics may make them more likely to benefit from micro-joys than others.
  • Studies show that people who are highly sensitive to their environment may disproportionately benefit from engaging in positive activities, such as micro-joys.
  • Here are a few ways you can practice finding joy in the little things:


Change your routine. Trying adding a 10-minute burst of joy into your normal morning, afternoon or evening routine which can give you a moment of delight to look forward to. For example, savouring a cup of tea.
Look out for moments of humour. Humour can be a great way to find joy each day. But if you find it hard to see joy in your day, try to imagine how your favourite comedian might hilariously interpret the events of your day.
Be spontaneous. Challenge your routine by introducing spontaneity into your day – even if you’re typically a meticulous planner. Embrace the unexpected – even if just for a rejuvenating, five-minute break to call a friend you haven’t spoken with in a while.
Pursue moments of connection and shared laughter with strangers, neighbour or acquaintances. Strengthening these social bonds can add a joy to your day.
Pause and appreciate. Taking regular breaks to savour the simple act of being alive throughout your day can bring a renewed sense of mindfulness and gratitude that result in joy. For example, listen to the birds singing, or allow yourself to laugh out loud when someone says something funny.
Engaging in small moments of joy daily holds the potential to elevate both short- and long-term wellbeing for many – though for some the impact of these activities will be more subtle than for others.
Jolanta Burke does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, February 6, 2024

ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).

Key Points: 
  • ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
  • U.S. Patent No.
  • 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases Associated With Viruses” generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, January 9, 2024

ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).

Key Points: 
  • ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
  • U.S. Patent No.
  • 11,865,329 entitled “Vagal Nerve Stimulation for Treating Post-Traumatic Stress Disorder” generally relates to methods for treating the symptoms of post-traumatic stress disorder (PTSD) that include applying one or more electrical impulses transcutaneously to the vagus nerve for approximately 90 seconds to approximately 3 minutes.
  • The electrical impulses may comprise bursts of 2 to 20 pulses.

Pulsetto Unveils Groundbreaking Vagus Nerve Stimulation Device at CES

Retrieved on: 
Thursday, January 4, 2024

Pulsetto, a leader in Vagus Nerve Stimulation technology, is showcasing at CES its unique dual-technology system and personalized app designed to alleviate stress, reduce anxiety, improve sleep, and manage pain, exemplifying a practical and everyday approach to enhancing mental wellness.

Key Points: 
  • Klaipeda County, Lithuania--(Newsfile Corp. - January 4, 2024) - Pulsetto is set to showcase at CES in Las Vegas, bringing its effective Vagus Nerve Stimulation (VNS) device into the spotlight.
  • A pivotal moment came when he encountered an article about vagus nerve stimulation, sparking the idea for Pulsetto.
  • This device innovatively activates the vagus nerve, a key player in regulating stress responses in the body.
  • On this note, Pulsetto invites all CES attendees to booth 8867 for a hands-on experience with its transformative Vagus Nerve Stimulation device.